Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 1998;31:349-355

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gohlke, P.
Right arrow Articles by Unger, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gohlke, P.
Right arrow Articles by Unger, T.

(Hypertension. 1998;31:349.)
© 1998 American Heart Association, Inc.


Scientific Contributions

AT2 Receptor Stimulation Increases Aortic Cyclic GMP in SHRSP by a Kinin-Dependent Mechanism

Peter Gohlke; Christiane Pees; Thomas Unger

Institute of Pharmacology, Christian-Albrechts University of Kiel and German Institute for High Blood Pressure Research, Heidelberg, Germany.

Correspondence to Peter Gohlke, PhD, Institute of Pharmacology, Christian-Albrechts University of Kiel, Hospitalstrasse 4, 24105 Kiel, Germany

In the present study we tested the hypothesis whether an angiotensin AT2 receptor-mediated stimulation of the bradykinin (BK)/nitric oxide (NO) system can account for the effects of AT1 receptor antagonism on aortic cGMP described previously in SHRSP. Adult SHRSP were treated for 4 hours with angiotensin II (ANG II) (30 ng/kg per min IV) or vehicle (0.9% NaCl IV). Animals were pretreated with vehicle, losartan (100 mg/kg PO), PD 123319 (30 mg/kg IV), losartan plus PD 123319, icatibant (500 µg/kg IV), NG-nitro-L-arginine methyl ester (L-NAME; 1 mg/kg IV), or minoxidil (3 mg/kg IV). Mean arterial blood pressure (MAP) was continuously monitored over the 4-hour experimental period, and plasma ANG II and aortic cGMP were measured by RIA at the end of the study. ANG II infusion over 4 hours raised MAP by about 20 mm Hg. Losartan alone or losartan plus ANG II as well as minoxidil plus ANG II markedly reduced blood pressure when compared to vehicle-treated or ANG II-treated animals, respectively. Plasma levels of ANG II were increased 2-fold by ANG II infusion alone or by ANG II in combination with icatibant, L-NAME, or minoxidil. The increase in plasma ANG II levels was even more pronounced after losartan treatment. Aortic cGMP content was significantly increased by ANG II, losartan, losartan plus ANG II, and minoxidil plus ANG II by 60%, 45%, 68%, and 52%, respectively (P<.05). The effects of ANG II and of losartan plus ANG II on aortic cGMP content were both blocked by cotreatment with the AT2 receptor antagonist PD 123319. Icatibant and L-NAME abolished the effects of ANG II on aortic cGMP. Our results demonstrate the following: (1) ANG II increases aortic cGMP by an AT2 receptor-mediated action because the effect could be prevented by an AT2 receptor antagonist; (2) the effect of ANG II was not secondary to blood pressure increase because it remained under reduction of MAP with minoxidil; (3) losartan increased aortic cGMP most likely by increasing plasma ANG II levels with a subsequent stimulation of AT2 receptors; and (4) the effects of AT2 receptor stimulation are mediated by BK and, subsequently, NO because they were abolished by B2 receptor blockade as well as by NO synthase inhibition.


Key Words: angiotensin II • AT1 receptor antagonist • AT2 receptor • bradykinin • nitric oxide • cGMP • losartan

Abbreviations: ANG II = angiotensin II • BK = bradykinin • L-NAME = NG-nitro-L-arginine methyl ester • MAP = mean arterial blood pressure • NO = nitric oxide • RAS = renin-angiotensin system • SHRSP = stroke-prone spontaneously hypertensive rats




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
F. S. Ramalho, I. Alfany-Fernandez, A. Casillas-Ramirez, M. Massip-Salcedo, A. Serafin, A. Rimola, V. Arroyo, J. Rodes, J. Rosello-Catafau, and C. Peralta
Are Angiotensin II Receptor Antagonists Useful Strategies in Steatotic and Nonsteatotic Livers in Conditions of Partial Hepatectomy under Ischemia-Reperfusion?
J. Pharmacol. Exp. Ther., April 1, 2009; 329(1): 130 - 140.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
A. K. Sampson, K. M. Moritz, E. S. Jones, R. L. Flower, R. E. Widdop, and K. M. Denton
Enhanced Angiotensin II Type 2 Receptor Mechanisms Mediate Decreases in Arterial Pressure Attributable to Chronic Low-Dose Angiotensin II in Female Rats
Hypertension, October 1, 2008; 52(4): 666 - 671.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
J. H. Lee, S. Xia, and L. Ragolia
Upregulation of AT2 receptor and iNOS impairs angiotensin II-induced contraction without endothelium influence in young normotensive diabetic rats
Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2008; 295(1): R144 - R154.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
M. E Johansson, B. Fagerberg, and G. Bergstrom
Angiotensin type 2 receptor is expressed in human atherosclerotic lesions
Journal of Renin-Angiotensin-Aldosterone System, March 1, 2008; 9(1): 17 - 21.
[Abstract] [PDF]


Home page
HypertensionHome page
P. Li, T. Kondo, Y. Numaguchi, K. Kobayashi, M. Aoki, N. Inoue, K. Okumura, and T. Murohara
Role of Bradykinin, Nitric Oxide, and Angiotensin II Type 2 Receptor in Imidapril-Induced Angiogenesis
Hypertension, February 1, 2008; 51(2): 252 - 258.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
D. C. Isbell, S. Voros, Z. Yang, J. M. DiMaria, S. S. Berr, B. A. French, F. H. Epstein, S. P. Bishop, H. Wang, R. J. Roy, et al.
Interaction between bradykinin subtype 2 and angiotensin II type 2 receptors during post-MI left ventricular remodeling
Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3372 - H3378.
[Abstract] [Full Text] [PDF]


Home page
Reproductive SciencesHome page
Kai Chen, D. C. Merrill, and J. C. Rose
The Importance of Angiotensin II Subtype Receptors for Blood Pressure Control During Mouse Pregnancy
Reproductive Sciences, October 1, 2007; 14(7): 694 - 704.
[Abstract] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
E. Messadi-Laribi, V. Griol-Charhbili, A. Pizard, M.-P. Vincent, D. Heudes, P. Meneton, F. Alhenc-Gelas, and C. Richer
Tissue Kallikrein Is Involved in the Cardioprotective Effect of AT1-Receptor Blockade in Acute Myocardial Ischemia
J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 210 - 216.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
V. C. Munk, L. Sanchez de Miguel, M. Petrimpol, N. Butz, A. Banfi, U. Eriksson, L. Hein, R. Humar, and E. J. Battegay
Angiotensin II Induces Angiogenesis in the Hypoxic Adult Mouse Heart In Vitro Through an AT2-B2 Receptor Pathway
Hypertension, May 1, 2007; 49(5): 1178 - 1185.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J. LeFebvre, A. Shintani, T. Gebretsadik, J. R. Petro, L. J. Murphey, and N. J. Brown
Bradykinin B2 Receptor Does Not Contribute to Blood Pressure Lowering during AT1 Receptor Blockade
J. Pharmacol. Exp. Ther., March 1, 2007; 320(3): 1261 - 1267.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
T. Juhlin, L. R. Erhardt, H. Ottosson, B. A.G. Jonsson, and P. Hoglund
Treatments with losartan or enalapril are equally sensitive to deterioration in renal function from cyclooxygenase inhibition
Eur J Heart Fail, February 1, 2007; 9(2): 191 - 196.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
V. Jankowski, R. Vanholder, M. van der Giet, M. Tolle, S. Karadogan, J. Gobom, J. Furkert, A. Oksche, E. Krause, T. N. Anh Tran, et al.
Mass-Spectrometric Identification of a Novel Angiotensin Peptide in Human Plasma
Arterioscler Thromb Vasc Biol, February 1, 2007; 27(2): 297 - 302.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
C. Savoia, R. M. Touyz, M. Volpe, and E. L. Schiffrin
Angiotensin Type 2 Receptor in Resistance Arteries of Type 2 Diabetic Hypertensive Patients
Hypertension, February 1, 2007; 49(2): 341 - 346.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
L. J. Salomone, N. L. Howell, H. E. McGrath, B. A. Kemp, S. R. Keller, J. J. Gildea, R. A. Felder, and R. M. Carey
Intrarenal Dopamine D1-Like Receptor Stimulation Induces Natriuresis via an Angiotensin Type-2 Receptor Mechanism
Hypertension, January 1, 2007; 49(1): 155 - 161.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
M. Paul, A. Poyan Mehr, and R. Kreutz
Physiology of local Renin-Angiotensin systems.
Physiol Rev, July 1, 2006; 86(3): 747 - 803.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
G. H. Goossens, S. E. McQuaid, A. L. Dennis, M. A. van Baak, E. E. Blaak, K. N. Frayn, W. H. M. Saris, and F. Karpe
Angiotensin II: a major regulator of subcutaneous adipose tissue blood flow in humans
J. Physiol., March 1, 2006; 571(2): 451 - 460.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
C. Warnecke, P. Mugrauer, D. Surder, J. Erdmann, C. Schubert, and V. Regitz-Zagrosek
Intronic ANG II type 2 receptor gene polymorphism 1675 G/A modulates receptor protein expression but not mRNA splicing
Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2005; 289(6): R1729 - R1735.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
E. Fossum, A. Moan, S. E. Kjeldsen, R. B. Devereux, S. Julius, S. M. Snapinn, J. M. Edelman, U. de Faire, F. Fyhrquist, H. Ibsen, et al.
The Effect of Losartan Versus Atenolol on Cardiovascular Morbidity and Mortality in Patients With Hypertension Taking Aspirin: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study
J. Am. Coll. Cardiol., September 6, 2005; 46(5): 770 - 775.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
L. M. Duke, R. G. Evans, and R. E Widdop
AT2 receptors contribute to acute blood pressure-lowering and vasodilator effects of AT1 receptor antagonism in conscious normotensive but not hypertensive rats
Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2289 - H2297.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
P. E. Walters, T. A. Gaspari, and R. E. Widdop
Angiotensin-(1-7) Acts as a Vasodepressor Agent Via Angiotensin II Type 2 Receptors in Conscious Rats
Hypertension, May 1, 2005; 45(5): 960 - 966.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
M. Gonzalez, L. Lobos, F. Castillo, L. Galleguillos, N. C. Lopez, and L. Michea
High-Salt Diet Inhibits Expression of Angiotensin Type 2 Receptor in Resistance Arteries
Hypertension, May 1, 2005; 45(5): 853 - 859.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. P. Forder, D. H. Munzenmaier, and A. S. Greene
Angiogenic protection from focal ischemia with angiotensin II type 1 receptor blockade in the rat
Am J Physiol Heart Circ Physiol, April 1, 2005; 288(4): H1989 - H1996.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. You, L. Loufrani, C. Baron, B. I. Levy, R. E. Widdop, and D. Henrion
High Blood Pressure Reduction Reverses Angiotensin II Type 2 Receptor-Mediated Vasoconstriction Into Vasodilation in Spontaneously Hypertensive Rats
Circulation, March 1, 2005; 111(8): 1006 - 1011.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
B. Somoza, M. C. Gonzalez, J. M. Gonzalez, F. Abderrahim, S. M. Arribas, and M. S. Fernandez-Alfonso
Modulatory role of the adventitia on noradrenaline and angiotensin II responses: Role of endothelium and AT2 receptors
Cardiovasc Res, February 1, 2005; 65(2): 478 - 486.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
E. Vazquez, I. Coronel, R. Bautista, E. Romo, C. M. Villalon, M. C. Avila-Casado, V. Soto, and B. Escalante
Angiotensin II-dependent induction of AT2 receptor expression after renal ablation
Am J Physiol Renal Physiol, January 1, 2005; 288(1): F207 - F213.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
M. M. Gironacci, M. S. Valera, I. Yujnovsky, and C. Pena
Angiotensin-(1-7) Inhibitory Mechanism of Norepinephrine Release in Hypertensive Rats
Hypertension, November 1, 2004; 44(5): 783 - 787.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
A. A Voors, P. P van Geel, M. Oosterga, H. Buikema, D. J van Veldhuisen, and W. H van Gilst
Vascular effects of quinapril completely depend on ACE insertion/deletion polymorphism
Journal of Renin-Angiotensin-Aldosterone System, September 1, 2004; 5(3): 130 - 134.
[Abstract] [PDF]


Home page
Circ. Res.Home page
S. Bergaya, R. H.P. Hilgers, P. Meneton, Y. Dong, M. Bloch-Faure, T. Inagami, F. Alhenc-Gelas, B. I. Levy, and C. M. Boulanger
Flow-Dependent Dilation Mediated by Endogenous Kinins Requires Angiotensin AT2 Receptors
Circ. Res., June 25, 2004; 94(12): 1623 - 1629.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
O. Johren, A. Dendorfer, and P. Dominiak
Cardiovascular and renal function of angiotensin II type-2 receptors
Cardiovasc Res, June 1, 2004; 62(3): 460 - 467.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
H. Hiyoshi, K. Yayama, M. Takano, and H. Okamoto
Stimulation of Cyclic GMP Production via AT2 and B2 Receptors in the Pressure-Overloaded Aorta After Banding
Hypertension, June 1, 2004; 43(6): 1258 - 1263.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
W. W. Batenburg, I. M. Garrelds, C. C. Bernasconi, L. Juillerat-Jeanneret, J. P. van Kats, P. R. Saxena, and A.H. J. Danser
Angiotensin II Type 2 Receptor-Mediated Vasodilation in Human Coronary Microarteries
Circulation, May 18, 2004; 109(19): 2296 - 2301.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
S. B. Ahmed, A. K. Kang, K. D. Burns, C. R. J. Kennedy, V. Lai, D. C. Cattran, J. W. Scholey, and J. A. Miller
Effects of Oral Contraceptive Use on the Renal and Systemic Vascular Response to Angiotensin II Infusion
J. Am. Soc. Nephrol., March 1, 2004; 15(3): 780 - 786.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
C. M. Bove, Z. Yang, W. D. Gilson, F. H. Epstein, B. A. French, S. S. Berr, S. P. Bishop, H. Matsubara, R. M. Carey, and C. M. Kramer
Nitric Oxide Mediates Benefits of Angiotensin II Type 2 Receptor Overexpression During Post-Infarct Remodeling
Hypertension, March 1, 2004; 43(3): 680 - 685.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
C. Tschope, F. Spillmann, C. Altmann, M. Koch, D. Westermann, N. Dhayat, S. Dhayat, J.-L. Bascands, L. Gera, S. Hoffmann, et al.
The bradykinin B1 receptor contributes to the cardioprotective effects of AT1 blockade after experimental myocardial infarction
Cardiovasc Res, February 15, 2004; 61(3): 559 - 569.
[Abstract] [Full Text] [PDF]


Home page
Innate ImmunityHome page
Z. Shariat-Madar and A. H. Schmaier
Review: The plasma kallikrein/kinin and renin angiotensin systems in blood pressure regulation in sepsis
Innate Immunity, February 1, 2004; 10(1): 3 - 13.
[Abstract] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
K. Yayama, M. Horii, H. Hiyoshi, M. Takano, H. Okamoto, S. Kagota, and M. Kunitomo
Up-Regulation of Angiotensin II Type 2 Receptor in Rat Thoracic Aorta by Pressure-Overload
J. Pharmacol. Exp. Ther., February 1, 2004; 308(2): 736 - 743.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
D. Kumar, V. Menon, W. R. Ford, A. S. Clanachan, and B. I. Jugdutt
Effect of Angiotensin II lype 2 Receptor Blockade on Activation of Mitogen-Activated Protein Kinases after Ischemia-Reperfusion in Isolated Working Rat Hearts
Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2003; 8(4): 285 - 296.
[Abstract] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
H. Thai, J. Wollmuth, S. Goldman, and M. Gaballa
Angiotensin Subtype 1 Receptor (AT1) Blockade Improves Vasorelaxation in Heart Failure by Up-Regulation of Endothelial Nitric-Oxide Synthase via Activation of the AT2 Receptor
J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 1171 - 1178.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
P. M. Abadir, R. M. Carey, and H. M. Siragy
Angiotensin AT2 Receptors Directly Stimulate Renal Nitric Oxide in Bradykinin B2-Receptor-Null Mice
Hypertension, October 1, 2003; 42(4): 600 - 604.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
B. I. Jugdutt and V. Menon
Upregulation of Angiotensin II Type 2 Receptor and Limitation of Myocardial Stunning by Angiotensin II Type 1 Receptor Blockers during Reperfused Myocardial Infarction in the Rat
Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2003; 8(3): 217 - 226.
[Abstract] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
A. H. Schmaier
The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction
Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2003; 285(1): R1 - R13.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
B. K Irons and A. Kumar
Valsartan-Induced Angioedema
Ann. Pharmacother., July 1, 2003; 37(7): 1024 - 1027.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
T. Itoh, J. Kajikuri, T. Tada, Y. Suzuki, and Y. Mabuchi
Angiotensin II-induced modulation of endothelium-dependent relaxation in rabbit mesenteric resistance arteries
J. Physiol., May 1, 2003; 548(3): 893 - 906.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
B. Hornig, C. Kohler, D. Schlink, H. Tatge, and H. Drexler
AT1-Receptor Antagonism Improves Endothelial Function in Coronary Artery Disease by a Bradykinin/B2-Receptor-Dependent Mechanism
Hypertension, May 1, 2003; 41(5): 1092 - 1095.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
T. Matsumoto, K. Minai, H. Horie, N. Ohira, H. Takashima, Y. Tarutani, Y. o Yasuda, T. Ozawa, S. Matsuo, M. Kinoshita, et al.
Angiotensin-converting enzyme inhibition but not angiotensin II type 1 receptor antagonism augments coronary release of tissue plasminogen activator in hypertensive patients
J. Am. Coll. Cardiol., April 16, 2003; 41(8): 1373 - 1379.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
I. Gavras and H. Gavras
Are Patients Who Develop Angioedema With ACE Inhibition at Risk of the Same Problem With AT1 Receptor Blockers?
Arch Intern Med, January 27, 2003; 163(2): 240 - 241.
[Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
S. Nakamura, D. B. Averill, M. C. Chappell, D. I. Diz, K. B. Brosnihan, and C. M. Ferrario
Angiotensin receptors contribute to blood pressure homeostasis in salt-depleted SHR
Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2003; 284(1): R164 - R173.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
C. Yan, D. Kim, T. Aizawa, and B. C. Berk
Functional Interplay Between Angiotensin II and Nitric Oxide: Cyclic GMP as a Key Mediator
Arterioscler Thromb Vasc Biol, January 1, 2003; 23(1): 26 - 36.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
R. De Caterina and C. Manes
Inflammation in early atherogenesis: impact of ACE inhibition
Eur. Heart J. Suppl., January 1, 2003; 5(suppl_A): A15 - A24.
[Abstract] [PDF]


Home page
Eur Heart J SupplHome page
L. Murphey, D. Vaughan, and N. Brown
Contribution of bradykinin to the cardioprotective effects of ACE inhibitors
Eur. Heart J. Suppl., January 1, 2003; 5(suppl_A): A37 - A41.
[Abstract] [PDF]


Home page
HypertensionHome page
S. Kurisu, R. Ozono, T. Oshima, M. Kambe, T. Ishida, H. Sugino, H. Matsuura, K. Chayama, Y. Teranishi, O. Iba, et al.
Cardiac Angiotensin II Type 2 Receptor Activates the Kinin/NO System and Inhibits Fibrosis
Hypertension, January 1, 2003; 41(1): 99 - 107.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Cai, Z. Li, S. Dikalov, S. M. Holland, J. Hwang, H. Jo, S. C. Dudley Jr., and D. G. Harrison
NAD(P)H Oxidase-derived Hydrogen Peroxide Mediates Endothelial Nitric Oxide Production in Response to Angiotensin II
J. Biol. Chem., December 6, 2002; 277(50): 48311 - 48317.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. A. F. de Godoy and A. M. de Oliveira
Cross-Talk Between AT1 and AT2 Angiotensin Receptors in Rat Anococcygeus Smooth Muscle
J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 333 - 339.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
R. E. Widdop, K. Matrougui, B. I. Levy, and D. Henrion
AT2 Receptor-Mediated Relaxation Is Preserved After Long-Term AT1 Receptor Blockade
Hypertension, October 1, 2002; 40(4): 516 - 520.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C.-C. Wei, C. M. Ferrario, K. B. Brosnihan, D. M. Farrell, W. E. Bradley, A. A. Jaffa, and L. J. Dell'Italia
Angiotensin Peptides Modulate Bradykinin Levels in the Interstitium of the Dog Heart in Vivo
J. Pharmacol. Exp. Ther., January 1, 2002; 300(1): 324 - 329.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
N. Uhlenius, O. Vuolteenaho, and I. Tikkanen
Renin-angiotensin blockade improves renal cGMP production via non-AT2-receptor mediated mechanisms in hypertension-induced by chronic NOS inhibition in rat
Journal of Renin-Angiotensin-Aldosterone System, December 1, 2001; 2(4): 233 - 239.
[Abstract] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C. Berry, R. Touyz, A. F. Dominiczak, R. C. Webb, and D. G. Johns
Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide
Am J Physiol Heart Circ Physiol, December 1, 2001; 281(6): H2337 - H2365.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
D. Henrion, N. Kubis, and B. I. Levy
Physiological and Pathophysiological Functions of the AT2 Subtype Receptor of Angiotensin II: From Large Arteries to the Microcirculation
Hypertension, November 1, 2001; 38(5): 1150 - 1157.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
Y.-p. Sun, B.-q. Zhu, A. E. M. Browne, S. Pulukurthy, T. M. Chou, K. Sudhir, S. A. Glantz, P. C. Deedwania, K. Chatterjee, and W. W. Parmley
Comparative Effects of ACE Inhibitors and an Angiotensin Receptor Blocker on Atherosclerosis and Vascular Function
Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2001; 6(2): 175 - 181.
[Abstract] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
B. I Jugdutt and M. Balghith
Enhanced regional AT2-receptor and PKC{varepsilon} expression during cardioprotection induced by AT1-receptor blockade after reperfused myocardial infarction
Journal of Renin-Angiotensin-Aldosterone System, June 1, 2001; 2(2): 134 - 140.
[Abstract] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
B. Johansson, M. Holm, S. Ewert, A. Casselbrant, A. Pettersson, and L. Fandriks
Angiotensin II type 2 receptor-mediated duodenal mucosal alkaline secretion in the rat
Am J Physiol Gastrointest Liver Physiol, June 1, 2001; 280(6): G1254 - G1260.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
T. Unger
Pharmacological properties of angiotensin II antagonists: examining all the therapeutic implications
Journal of Renin-Angiotensin-Aldosterone System, June 1, 2001; 2(2_suppl): S4 - S7.
[Abstract] [PDF]


Home page
HypertensionHome page
J. Varagic, D. Susic, and E. D. Frohlich
Coronary Hemodynamic and Ventricular Responses to Angiotensin Type 1 Receptor Inhibition in SHR : Interaction With Angiotensin Type 2 Receptors
Hypertension, June 1, 2001; 37(6): 1399 - 1403.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
R. Bravo, B. Somoza, M. Ruiz-Gayo, C. Gonzalez, L. M. Ruilope, and M. S. Fernandez-Alfonso
Differential Effect of Chronic Antihypertensive Treatment on Vascular Smooth Muscle Cell Phenotype in Spontaneously Hypertensive Rats
Hypertension, May 1, 2001; e10(5): .
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
B. I Jugdutt, Yi Xu, M. Balghith, and V. Menon
Cardioprotective effects of angiotensin II type 1 receptor blockade with candesartan after reperfused myocardial infarction: role of angiotensin II type 2 receptor
Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S162 - S166.
[Abstract] [PDF]


Home page
CirculationHome page
B. Hornig, U. Landmesser, C. Kohler, D. Ahlersmann, S. Spiekermann, A. Christoph, H. Tatge, and H. Drexler
Comparative Effect of ACE Inhibition and Angiotensin II Type 1 Receptor Antagonism on Bioavailability of Nitric Oxide in Patients With Coronary Artery Disease : Role of Superoxide Dismutase
Circulation, February 13, 2001; 103(6): 799 - 805.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. E. Schmieder, J. Erdmann, C. Delles, J. Jacobi, E. Fleck, K. Hilgers, and V. Regitz-Zagrosek
Effect of the angiotensin II type 2-receptor gene (+1675 G/A) on left ventricular structure in humans
J. Am. Coll. Cardiol., January 1, 2001; 37(1): 175 - 182.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Lauth, M. Cattaruzza, and M. Hecker
ACE Inhibitor and AT1 Antagonist Blockade of Deformation-Induced Gene Expression in the Rabbit Jugular Vein Through B2 Receptor Activation
Arterioscler Thromb Vasc Biol, January 1, 2001; 21(1): 61 - 66.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
G. Nickenig, A. Stablein, S. Wassmann, C. Wyen, C. Muller, and M. Bohm
Acute effects of ACE inhibition on coronary endothelial dysfunction
Journal of Renin-Angiotensin-Aldosterone System, December 1, 2000; 1(4): 361 - 364.
[Abstract] [PDF]


Home page
Pharmacol. Rev.Home page
R. M. Touyz and E. L. Schiffrin
Signal Transduction Mechanisms Mediating the Physiological and Pathophysiological Actions of Angiotensin II in Vascular Smooth Muscle Cells
Pharmacol. Rev., December 1, 2000; 52(4): 639 - 672.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J. A. Olivares-Reyes, S. Jayadev, L. Hunyady, K. J. Catt, and R. D. Smith
Homologous and Heterologous Phosphorylation of the AT2 Angiotensin Receptor by Protein Kinase C
Mol. Pharmacol., November 1, 2000; 58(5): 1156 - 1161.
[Abstract] [Full Text]


Home page
J. Am. Soc. Nephrol.Home page
M. C. DE GRACIA, A. OSUNA, F. O'VALLE, R. G. DEL MORAL, R. WANGENSTEEN, C. G. DEL RIO, and F. VARGAS
Deoxycorticosterone Suppresses the Effects of Losartan in Nitric Oxide--Deficient Hypertensive Rats
J. Am. Soc. Nephrol., November 1, 2000; 11(11): 1995 - 2000.
[Abstract] [Full Text]


Home page
HypertensionHome page
Y. Xu, A. S. Clanachan, and B. I. Jugdutt
Enhanced Expression of Angiotensin II Type 2 Receptor, Inositol 1,4,5-Trisphosphate Receptor, and Protein Kinase C{epsilon} During Cardioprotection Induced by Angiotensin II Type 2 Receptor Blockade
Hypertension, October 1, 2000; 36(4): 506 - 510.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
K. D. Croft, J. C. McGiff, A. Sanchez-Mendoza, and M. A. Carroll
Angiotensin II releases 20-HETE from rat renal microvessels
Am J Physiol Renal Physiol, September 1, 2000; 279(3): F544 - F551.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
H. Kraiczi, J. Hedner, Y. Peker, and J. Carlson
Increased vasoconstrictor sensitivity in obstructive sleep apnea
J Appl Physiol, August 1, 2000; 89(2): 493 - 498.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. E. Bishop, L. A. Kiernan, H. E. Montgomery, P. Gohlke, and J. R. McEwan
Raised blood pressure, not renin-angiotensin systems, causes cardiac fibrosis in TGR m(Ren2)27 rats
Cardiovasc Res, July 1, 2000; 47(1): 57 - 67.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
M. d. Gasparo, P. Hess, B. Nuesslein-Hildesheim, P. Bruneval, and J.-P. Clozel
Combination of non-hypotensive doses of valsartan and enalapril improves survival of spontaneously hypertensive rats with endothelial dysfunction
Journal of Renin-Angiotensin-Aldosterone System, June 1, 2000; 1(2): 151 - 158.
[Abstract] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
A. Nunez, J. Gomez, L. R. Zalba, M. Monton, A. Jimenez, S. Velasco, A. Lopez-Blaya, A. Celdran Uriarte, S. Casado, and A. Lopez-Farre
Losartan inhibits in vitro platelet activation: comparison with candesartan and valsartan
Journal of Renin-Angiotensin-Aldosterone System, June 1, 2000; 1(2): 175 - 179.
[Abstract] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
Yi Xu, V. Menon, and B. I Jugdutt
Cardioprotection after angiotensin II type 1 blockade involves angiotensin II type 2 receptor expression and activation of protein kinase C-{varepsilon} in acutely reperfused myocardial infarction in the dog: Effect of UP269-6 and losartan on AT1- and AT2-receptor expression and IP3 receptor and PKC{varepsilon} proteins
Journal of Renin-Angiotensin-Aldosterone System, June 1, 2000; 1(2): 184 - 195.
[Abstract] [PDF]


Home page
HypertensionHome page
W. Linz, H. Heitsch, B. A. Scholkens, and G. Wiemer
Long-Term Angiotensin II Type 1 Receptor Blockade With Fonsartan Doubles Lifespan of Hypertensive Rats
Hypertension, April 1, 2000; 35(4): 908 - 913.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
M. Schachter
ACE inhibitors, angiotensin receptor antagonists and bradykinin
Journal of Renin-Angiotensin-Aldosterone System, March 1, 2000; 1(1): 27 - 29.
[PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
S. Gallinat, S. Busche, M. K. Raizada, and C. Sumners
The angiotensin II type 2 receptor: an enigma with multiple variations
Am J Physiol Endocrinol Metab, March 1, 2000; 278(3): E357 - E374.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
D.J. van Veldhuisen and A.A. Voors
Blockade of the renin angiotensin system in heart failure: the potential place of angiotensin II receptor blockers
Eur. Heart J., January 1, 2000; 21(1): 14 - 16.
[PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
B. I. Jugdutt, Yi Xu, M. Balghith, R. Moudgil, and V. Menon
Cardioprotection Induced by AT1R Blockade After Reperfused Myocardial Infarction: Association With Regional Increase in AT2R, IP3R and PKC{varepsilon} Proteins and cGMP
Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(4): 301 - 311.
[Abstract] [PDF]


Home page
HypertensionHome page
R. M. Carey, Z.-Q. Wang, and H. M. Siragy
Role of the Angiotensin Type 2 Receptor in the Regulation of Blood Pressure and Renal Function
Hypertension, January 1, 2000; 35(1): 155 - 163.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
H. MATSUDA, K. HAYASHI, K. ARAKAWA, M. NAITOH, E. KUBOTA, M. HONDA, A. MATSUMOTO, H. SUZUKI, T. YAMAMOTO, F. KAJIYA, et al.
Zonal Heterogeneity in Action of Angiotensin-Converting Enzyme Inhibitor on Renal Microcirculation: Role of Intrarenal Bradykinin
J. Am. Soc. Nephrol., November 1, 1999; 10(11): 2272 - 2282.
[Abstract] [Full Text]


Home page
HypertensionHome page
M. N. Barber, D. B. Sampey, and R. E. Widdop
AT2 Receptor Stimulation Enhances Antihypertensive Effect of AT1 Receptor Antagonist in Hypertensive Rats
Hypertension, November 1, 1999; 34(5): 1112 - 1116.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
K. Matrougui, L. Loufrani, C. Heymes, B. I. Levy, and D. Henrion
Activation of AT2 Receptors by Endogenous Angiotensin II Is Involved in Flow-Induced Dilation in Rat Resistance Arteries
Hypertension, October 1, 1999; 34(4): 659 - 665.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
K. C Wollert and H. Drexler
The renin-angiotensin system and experimental heart failure
Cardiovasc Res, September 1, 1999; 43(4): 838 - 849.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
W. Linz, P. Wohlfart, B. A Scholkens, T. Malinski, and G. Wiemer
Interactions among ACE, kinins and NO
Cardiovasc Res, August 15, 1999; 43(3): 549 - 561.
[Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
H. M. Siragy, T. Inagami, T. Ichiki, and R. M. Carey
Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor
PNAS, May 25, 1999; 96(11): 6506 - 6510.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
H. M. Siragy and R. M. Carey
Protective Role of the Angiotensin AT2 Receptor in a Renal Wrap Hypertension Model
Hypertension, May 1, 1999; 33(5): 1237 - 1242.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
M. Horiuchi, M. Akishita, and V. J. Dzau
Recent Progress in Angiotensin II Type 2 Receptor Research in the Cardiovascular System
Hypertension, February 1, 1999; 33(2): 613 - 621.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
N. H. Anderson, A. M. Devlin, D. Graham, J. J. Morton, C. A. Hamilton, J. L. Reid, N. J. Schork, and A. F. Dominiczak
Telemetry for Cardiovascular Monitoring in a Pharmacological Study : New Approaches to Data Analysis
Hypertension, January 1, 1999; 33(1): 248 - 255.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
H. Matsubara
Pathophysiological Role of Angiotensin II Type 2 Receptor in Cardiovascular and Renal Diseases
Circ. Res., December 14, 1998; 83(12): 1182 - 1191.
[Abstract] [Full Text] [PDF]